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Abstract
Background: Tyrosine kinase inhibitors (TKIs) have gained much attention in recent years as
targeted agents for the treatment of a wide range of human cancers. We have investigated the
effect of the TKIs gefitinib and vandetanib on tumor cell lines derived from Ewing sarcoma, a highly
malignant tumor affecting bone and soft tissue in children and young adults. Gefitinib is an inhibitor
of epidermal growth factor receptor tyrosine kinase activity (EGFR) and vandetanib selectively
targets vascular endothelial growth factor receptor-2 (VEGFR-2) with additional activity against
VEGFR-3, EGFR and RET kinase receptors.
Results: Two Ewing sarcoma cell lines investigated showed high levels of nuclear EGFR expression
as well as moderate expression in plasma membrane and cytoplasm. When treated with
concentrations of 5 μM and more of either gefitinib or vandetanib, we observed a significant
decrease in cell proliferation. However, there were no detectable changes in p44/42 MAPK and
Akt-1 phosphorylation, or in the expression of cyclin D1 or c-Myc following gefitinib or vandetanib
treatment.
Conclusion: We conclude that Ewing sarcoma tumor cell proliferation is not highly sensitive to
inhibition of EGFR signaling alone or the simultaneous inhibition of VEGFR receptors, EGFR and
RET kinase. Decreased tumor cell proliferation could be achieved with gefitinib and vandetanib, but
only at higher doses where non-specific effects of the compounds may be overriding. As Ewing
tumor cells do not seem to depend on EGFR and VEGFR pathways for survival, other key factors
in the cellular signaling of Ewing sarcoma should be targeted in order to obtain a potent therapeutic
response.
Background
The Ewing sarcoma family of tumors (ESFTs) is a group of
highly malignant tumors affecting bone and soft tissue in
children and young adults. ESFT are characterized by
reciprocal chromosomal translocations involving the
EWSR1 gene and members of the ets gene family. Multi-
modal treatment cures about 60% of patients with a local-
ized tumor; however, patients not responsive to therapy,
those with detectable metastases at diagnosis and patients
with recurrent disease, have a much poorer prognosis,
with a cure rate of less than 20%. New therapeutic regi-
mens are therefore needed to treat these diseases [1,2].
Tyrosine kinases are a family of enzymes that are impor-
tant mediators of signal transduction. They function by
selectively phosphorylating target proteins on specific
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tyrosine residues, using ATP as a substrate. The
observation that tyrosine kinases are frequently mutated
or otherwise deregulated in human malignancies has led
to the emergence of these enzymes as important therapeu-
tic targets in cancer. This has prompted the development
and clinical application of tyrosine kinase inhibitors
(TKIs) across a broad spectrum of malignancies. TKIs are
small organic molecules that inhibit the kinase activity of
specific tyrosine kinases by blocking their ATP binding
pocket[3].
The aim of this study was to investigate the antiprolifera-
tive effect of the TKIs gefitinib (IRESSA™, ZD1839) and
vandetanib (ZACTIMA™, ZD6474) on two Ewing sarcoma
cell lines. Gefitinib, an inhibitor of epidermal growth fac-
tor receptor (EGFR) tyrosine kinase activity, is approved in
certain markets for the treatment of non-small cell lung
cancer (NSCLC) [4-6]. In addition, a prior study showed
partial response for gefitinib in one patient diagnosed
with recurrent Ewing sarcoma [7]. Vandetanib, a selective
inhibitor of vascular endothelial growth factor receptor
(VEGFR), EGFR and RET receptor kinase signaling [8-10],
has recently entered Phase III clinical development in
NSCLC.
Earlier studies have shown that treatment of tumor cells
with TKIs targeting the EGFR family of receptors downreg-
ulates mitogen-activated protein kinase (MAPK) and
phosphatidylinositol-3-kinase (PI3K)-Akt signaling
(reviewed in Hynes and Lane [11]). Consequently, we
assessed the effects of gefitinib and vandetanib on down-
stream targets in these pathways [12,13]).
Results
EWS TC71 and EWS IOR/CAR cell lines express EGFR
EGFR expression was confirmed by immunofluorescent
imaging (Fig. 1). Both cell lines showed EGFR expression
in the plasma membrane and cytoplasm, as well as high
levels of nuclear accumulation.
Gefitinib and vandetanib inhibit growth of Ewing sarcoma 
cell lines
Growth of the EWS TC71 cell line was markedly inhibited
by both drugs with a significant antiproliferative effect
observed at 5 μM gefitinib and 1 μM vandetanib (Fig. 2).
The IC50 values for gefitinib and vandetanib in EWS TC71
were estimated to be ~10 μM and ~5 μM, respectively. The
EWS IOR/CAR cell line was less sensitive to TKI treatment
but still demonstrated significant growth suppression at 5
μM gefitinib or vandetanib (Fig. 2). IC50 values could not
be calculated for the EWS IOR/CAR following 72 hours of
treatment with 1–20 μM of either drug.
Gefitinib and vandetanib have no effect on P44/42 MAPK/
Akt-1 phosphorylation and cyclin D1/c-Myc expression
Deregulation of cellular signaling in cells treated with the
two tyrosine kinase inhibitors was analyzed by studying
p44/42 MAPK and Akt-1 phosphorylation as well as cyclin
D1 and c-Myc protein levels. Phosphorylated Akt-1 was
detected in the EWS IOR/CAR cell line but not in EWS
TC71 cells whereas phosphorylated p44/p42 MAPK was
detected in the EWS TC71 cell line but only at low levels
in EWS IOR/CAR cells (Fig. 3). The phosphorylation sta-
tus of both proteins was unchanged following incubation
with 10 μM gefitinib or vandetanib (Fig 3.) Neither cyclin
D1 nor c-Myc expression patterns were altered in drug
treated cells compared with untreated control cells
(Fig. 3).
Discussion
In this study, the antiproliferative effect of gefitinib and
vandetanib was investigated in two Ewing sarcoma cell
lines. We initially examined EGFR expression in both cell
lines and found that EGFR is present as aggregates in the
tumor cell nuclei as well as localized to the plasma mem-
brane and cytoplasm. Previous studies have shown that
nuclear accumulation of EGFR correlates with poor prog-
nosis in breast cancer and oropharyngeal squamous
cell carcinomas [14,15]. The aberrant nuclear EGFR
expression in our cell lines was taken as confirmation that
Ewing tumor cells overexpressing EGFR Figure 1
Ewing tumor cells overexpressing EGFR. Cells (EWS 
TC71 and EWS IOR/CAR) were fixed and stained for EGFR 
using rabbit polyclonal antibodies, which were visualized with 
goat Cy3-conjugated secondary antibodies. Images show Cy3 
fluorescence (left), DAPI staining of nuclei (middle) and merge 
(right). Images were recorded by laser scanning microscopy. 
Bars indicate 10 μM.Cancer Cell International 2008, 8:1 http://www.cancerci.com/content/8/1/1
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the cells used in this study were appropriate models for
investigating EGFR targeted treatment.
Proliferation of the tumor cell lines was significantly
inhibited in the presence of gefitinib or vandetanib. How-
ever, the IC50 values obtained with EWS TC71 (~10 μM
and ~5 μM for gefitinib and vandetanib, respectively)
were markedly higher than the nanomolar concentrations
of gefitinib and vandetanib observed to inhibit EGFR and
VEGFR-2 kinase activity in vitro [5,10]. This suggests that
the inhibition of EGFR alone or combined inhibition of
EGFR, VEGFR2 and RET did not have potent effects on cell
proliferation with the culture conditions used in the
present study. At high concentrations of gefitinib or van-
detanib, significant inhibition of Ewing sarcoma tumour
cell growth (>1 μM vandetanib, >5 μM gefitinib) was
acheieved but this inhibition is most likely due to off-tar-
get effects. The EWS IOR/CAR cell line was less sensitive to
both gefitinib and vandetanib and IC50 values could not
be determined following drug treatment of this cell line in
the concentration range tested. Differential sensitivity to
EGFR inhibitors have been previously reported for a large
panel of cancer cell lines with varying degrees of EGFR
expression [16].
Deregulation of cellular signaling in cells treated with
gefitinib and vandetanib was analyzed by studying p44/
42 MAPK and Akt-1 phosphorylation following serum
stimulation in conjunction with drug treatment. We also
investigated cyclin D1 and c-Myc protein levels under the
same conditions since both cyclin D1 and c-Myc are
important downstream targets in EGFR signaling [12,13].
Neither gefitinib nor vandetanib had an effect on p44/42
MAPK and Akt-1 phosphorylation. Surprisingly, discrep-
ancies in the levels of phosphorylated p44/42 MAPK and
Akt-1 were observed between the cell lines, with the EWS
TC71 cell line lacking phosphorylated Akt-1 and the EWS
IOR/CAR line showing only small amounts of phosphor-
ylated p44/42 MAPK. Thus, there are clearly differences
between the cell lines with respect to activation of, and
dependence on, MAPK and PI3K-AKT pathways. These
observations contrast with earlier findings demonstrating
constitutive activation of the MAPK and PI3K-AKT path-
ways in Ewing sarcoma cell lines [17]. Furthermore, we
did not detect any changes in cyclin D1 or c-Myc levels
when cells were incubated with gefitinib or vandetanib.
However, the incubation time used in this study might be
too short to elicit a change in the protein levels of cyclin
D1 and c-Myc. We presume that the treatment with TKIs
Proliferation of Ewing tumor cells treated with tyrosine kinase inhibitors for 72 hours Figure 2
Proliferation of Ewing tumor cells treated with tyrosine kinase inhibitors for 72 hours. Cells were treated with 
indicated concentrations of drugs and relative cell proliferation was assayed in comparison to untreated control cells. Results 
shown are the means of ten replicates and error bars show 95.0% confidence interval of mean. Asterisks indicate significant 
inhibition of proliferation at p values indicated in the figures. Data represents one of three experiments yielding similar results.Cancer Cell International 2008, 8:1 http://www.cancerci.com/content/8/1/1
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would rapidly prevent phosphorylation of MAPK and
PI3K-AKT but the activation of these proteins does not
appear to be dependent on EGFR- and VEGFR-mediated
signaling in the cell lines used in this study. Several dereg-
ulated growth factor circuits have been described for
Ewing sarcoma cells in the literature such as signaling
through the insulin-like growth factor I receptor [18], by
human gastrin-releasing peptide [19] and basic fibroblast
growth factor [20], as well as platelet derived growth fac-
tor[21,22]. Any of these pathways could be involved in
the activation of MAPK and PI3K-AKT signaling in the
cells studied.
Inhibition of EGFR or VEGFR-2 signaling by gefitinib or
vandetanib is inadequate to inhibit tumor cell prolifera-
tion in vitro other than through unspecific toxicity. Hence,
the survival of Ewing sarcoma cells in culture does not
seem to depend on EGFR or VEGFR signaling alone. Other
growth stimulatory pathways that are essential for tumor
cell viability must be targeted in order to obtain a thera-
peutic response, may it be simultaneously with EGFR/
VEGFR-2 inhibition or by other means. Previous work has
reported that gefitinib in combination with standard cyto-
toxic agents potentiates the antitumor activity and results
in prolonged survival of mice compared to gefitinib or
cytotoxic agents alone [23]. Moreover, studies have shown
that response to gefitinib and vandetanib correlate with
mutation status of EGFR [24-27], the status of which is
unknown for the cell lines used in this study. Although,
no mutations were found in the EGFR gene in the one
patient treated with gefitinib showing partial response [7].
Conclusion
We conclude that the sole inhibition of EGFR or VEGFR-2
signaling in Ewing sarcoma cell lines is not sufficient to
inhibit tumor cell proliferation other than through unspe-
cific toxicity. Thus, a deeper understanding of the specific
factors required for Ewing tumor cell proliferation, the
sensitivity of different subtypes, and which of these are
inhibited by combinations of drug treatments, will further
aid the means of targeting the disease from multiple
standpoints and in the process avoiding acquired resist-
ance.
Methods
Cell lines
EWS TC71 (expressing EWS-FLI1) and EWS IOR/CAR
(expressing EWS-ERG) cell lines were kind gifts from Dr.
Katia Scotlandi (Laboratory of Oncologic Research,
Orthopaedic Rizzoli Institute, Bologna, Italy). Cells were
maintained in IMDM medium (PAA Laboratories GmbH,
Austria) supplemented with 10% fetal bovine serum
(FBS), penicillin (50 U/ml) and streptomycin (50 μg/ml)
at 37°C in 5% CO2.
Reagents
Gefitinib and vandetanib were generously provided by
AstraZeneca Pharmaceuticals (Macclesfield, UK). Gefit-
inib and vandetanib were dissolved in dimethylsulfoxide
(DMSO) at stock concentrations of 10 mM and 50 mM,
respectively, and stored at -20°C. Drugs were further
diluted in growth medium prior to experiments.
Immunofluorescence
Approximately 2 × 105 tumor cells were seeded and grown
in Lab-Tek flaskettes (Nalge Nunc International) for two
days and then fixed in 3.7% formaldehyde in phosphate-
buffered saline (PBS). Fixed cells were stained for EGFR
with a rabbit polyclonal antibody (sc-03, Santa Cruz Bio-
technology) and visualized using goat anti-rabbit Cy3-
conjugated secondary antibodies (PA43004, Amersham
Biosciences). Slides were mounted in ProLong Gold Anti-
fade with DAPI (Molecular Probes) and imaged using a
Zeiss LSM510 META confocal microscope.
Proliferation assay
Tumor cells (~5 × 102) were seeded in each well of black
walled/clear bottom 96-well plates (BD Falcon) pre-
treated with Collagen R (Serva Electrophoresis) and
allowed to adhere overnight. The following day, gefitinib
or vandetanib (0 to 20 μM) were added; a total of 10
Effects on MAPK and PI3K-AKT pathways following treat- ment with tyrosine kinase inhibitors Figure 3
Effects on MAPK and PI3K-AKT pathways following 
treatment with tyrosine kinase inhibitors. Cells were 
serum starved for 24 hours and then incubated for 1 hour 
with 10 μM gefitinib or vandetanib. Following this, cells were 
stimulated with medium containing 10% fetal bovine serum 
for 4 hours, still in the presence of 10 μM gefitinib or vande-
tanib. Control cells were treated with vehicle (DMSO) only. 
Cell extracts were analyzed by western blot using β-actin as 
a loading control.Cancer Cell International 2008, 8:1 http://www.cancerci.com/content/8/1/1
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replicates were used for each concentration. Control cells
were incubated with equivalent volumes of DMSO. After
72 hours, cells were subjected to multiple freeze-thaw
lyses at -84°C and 37°, respectively. Cell proliferation rel-
ative to untreated control cells was assayed with a
CyQuant Cell Proliferation Assay Kit (Molecular Probes)
using a SpectraMaxGeminiXS microplate reader (Molecu-
lar Devices). The IC50 of the drugs was defined as the con-
centration required for reducing the cell number to 50%
of the control.
Western blotting
Approximately 5 × 105 tumor cells were seeded and grown
on Cell+ tissue culture dishes (Sarstedt) pre-treated with
Collagen R (Serva Electrophoresis) and allowed to adhere
over night. The following day, cells were incubated with
serum-free medium for 24 hours and then treated with 10
μM of either gefitinib or vandetanib for 1 hour in the
same medium. Controls were treated with corresponding
volumes of vehicle (DMSO). Cells were then stimulated
for 4 additional hours in medium containing full serum
(10% FBS), still in the presence of gefitinib or vandetanib
(10 μM). Following stimulation, cells were scraped off
and lysed in radioimmunoprecipitation assay (RIPA)
buffer containing 1× Complete Mini Protease Inhibitor
(Roche), 50 mM NaF and 1 mM heat-activated Na3VO4.
Samples were run on NuPage 4–12% Bis-Tris gels (Invit-
rogen) using MOPS running buffer and blotted onto
PVDF membranes (Immobilon). Blots were stained with
antibodies for p44/42 MAPK (137F5, Cell Signaling Tech-
nology), phospho-p44/42 MAPK (20G11, Cell Signaling
Technology), Akt1 (2H10, Cell Signaling Technology),
phospho-Akt (587F11, Cell Signaling Technology), cyclin
D1 (M7155, DakoCytomation), c-Myc (sc-40, Santa Cruz
Biotechnology) and β-actin (sc-8432, Santa Cruz Biotech-
nology). Membranes were incubated with alkaline phos-
phatase-conjugated secondary antibodies (D 0306 and D
0314, DakoCytomation) and visualized with BCIP/NBT
tablets (Sigma).
Statistical methods
Independent samples t-test was used to detect significant
differences in proliferation between TKI-treated cells and
untreated control cells. All statistical tests were two-tailed.
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